Empirican PRN, Inc. — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$9,033	5
2023	Research	$18,681	12
2022	Research	$5,930	3

Breakdown

Who paid Research payments · program years 2022–2025

Alnylam Pharmaceuticals Inc. $9,986 1 payment
Daiichi Sankyo Inc. $9,033 5 payments
Sumitomo Pharma America, Inc. $8,695 11 payments
Urovant Sciences Inc $5,930 3 payments

Studies the money was for Research payments · program years 2022–2025

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) $9,986 1 payment
Ds1062-328 $9,033 5 payments
Composur, A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder $7,731 5 payments
A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder $6,894 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.